肺积方联合化疗治疗气阴两虚证非小细胞肺癌患者的临床观察(1)
参见附件(12kb)。
(1.杭州市红十字会医院肿瘤科，浙江 杭州 310003；2.浙江中医药大学附属第三医院呼吸内科，浙江 杭州 310005)
摘 要：目的：通过对非小细胞肺癌患者免疫功能、生存质量变化情况研究，观察肺积方联合化疗治疗气阴两虚证非小细胞肺癌患者的临床疗效，为肺积方的临床应用提供客观依据。方法：采用随机对照研究方法，将70例经明确诊断的非小细胞肺癌患者随机分为治疗组(肺积方+化疗，n35)和对照组(化疗组，n35)，从患者生存质量、主要临床症状、免疫功能三方面评价肺积方联合化疗治疗非小细胞肺癌的临床疗效。结果：治疗组生存质量改善情况明显优于对照组(P<0.05)；与对照组相比，治疗组可降低外周血CD+8水平和提高CD+3、CD+4、CD+4/CD+8比值以及NK细胞活性水平，促进患者白介素2表达(P<0.05)。结论：肺积方联合化疗可以提高非小细胞肺癌患者的生存质量，改善患者的临床症状，并在一定程度上提高机体的免疫能力。
关键词：肺积方；非小细胞肺癌；临床观察
中图分类号：R734.2文献标识码：A文章编号：1673-7717(2011)03-0663-04
The Clinical Study on the Patients with Non-small Lung Cancer Interfered by
Fei Ji Fang Combined with Chemotherepy
YANG Guo-liang1，ZHANG Xue-jin1，HU Dan-dan2
(1.Hangzhou Red Cross Hospital of Zhejiang province,Hangzhou 310003,Zhejiang,China;
2.The Third Hospital of Zhejiang University of Traditional Chinese Medicine,Hangzhou 310005,Zhejiang,China)
Abstract:Objective: To observe the effect of FeiJi Fang combined with chemotherepy on the quality of life of the patients with non-small lung cancer ,and the regulation of immune function for providing the clinical proof for the above model.Methods: It is a prospective, randomized, parallel-control study. 70 patients with a clear diagnosis of the non-small lung cancer patients were randomly divided into intervention group (Fei Ji Fang treatment combined with chemotherepy, n35) and control group (chemotherepy treatment, n35).Recording and evaluating the variation of quality of life,between the two groups at the beginning and after the the treatment, at the same time contrasting the variation of peripheral blood lymphocyte subsets of T 、IL-2 and NK activity between two groups.Results: Improved points on quality of life of the intervention group were better than the control group. Compared with the control group, the level of CD+8 in the intervention group was lower than the control group after the treatment .The level of CD+3, CD+4, CD+4 /CD+8 ratio and the level of NK cell activity was higher than the control group. Conclusions: FeiJi Fang combined with chemotherepy can improve the immune function and the quality of life of the non-small lung cancer patients. ......
(1.杭州市红十字会医院肿瘤科，浙江 杭州 310003；2.浙江中医药大学附属第三医院呼吸内科，浙江 杭州 310005)
摘 要：目的：通过对非小细胞肺癌患者免疫功能、生存质量变化情况研究，观察肺积方联合化疗治疗气阴两虚证非小细胞肺癌患者的临床疗效，为肺积方的临床应用提供客观依据。方法：采用随机对照研究方法，将70例经明确诊断的非小细胞肺癌患者随机分为治疗组(肺积方+化疗，n35)和对照组(化疗组，n35)，从患者生存质量、主要临床症状、免疫功能三方面评价肺积方联合化疗治疗非小细胞肺癌的临床疗效。结果：治疗组生存质量改善情况明显优于对照组(P<0.05)；与对照组相比，治疗组可降低外周血CD+8水平和提高CD+3、CD+4、CD+4/CD+8比值以及NK细胞活性水平，促进患者白介素2表达(P<0.05)。结论：肺积方联合化疗可以提高非小细胞肺癌患者的生存质量，改善患者的临床症状，并在一定程度上提高机体的免疫能力。
关键词：肺积方；非小细胞肺癌；临床观察
中图分类号：R734.2文献标识码：A文章编号：1673-7717(2011)03-0663-04
The Clinical Study on the Patients with Non-small Lung Cancer Interfered by
Fei Ji Fang Combined with Chemotherepy
YANG Guo-liang1，ZHANG Xue-jin1，HU Dan-dan2
(1.Hangzhou Red Cross Hospital of Zhejiang province,Hangzhou 310003,Zhejiang,China;
2.The Third Hospital of Zhejiang University of Traditional Chinese Medicine,Hangzhou 310005,Zhejiang,China)
Abstract:Objective: To observe the effect of FeiJi Fang combined with chemotherepy on the quality of life of the patients with non-small lung cancer ,and the regulation of immune function for providing the clinical proof for the above model.Methods: It is a prospective, randomized, parallel-control study. 70 patients with a clear diagnosis of the non-small lung cancer patients were randomly divided into intervention group (Fei Ji Fang treatment combined with chemotherepy, n35) and control group (chemotherepy treatment, n35).Recording and evaluating the variation of quality of life,between the two groups at the beginning and after the the treatment, at the same time contrasting the variation of peripheral blood lymphocyte subsets of T 、IL-2 and NK activity between two groups.Results: Improved points on quality of life of the intervention group were better than the control group. Compared with the control group, the level of CD+8 in the intervention group was lower than the control group after the treatment .The level of CD+3, CD+4, CD+4 /CD+8 ratio and the level of NK cell activity was higher than the control group. Conclusions: FeiJi Fang combined with chemotherepy can improve the immune function and the quality of life of the non-small lung cancer patients. ......
您现在查看是摘要介绍页，详见PDF附件(12kb)。